loading page

Complete hematological and major molecular response through treatment with ultra-low dose Interferon alpha 2 in polycythemia vera: a case report
  • +1
  • Christoph Driessen,
  • Christoph Noppen,
  • Georg Boonen,
  • Juergen Drewe
Christoph Driessen
Kantonsspital Sankt Gallen
Author Profile
Christoph Noppen
Viollier AG
Author Profile
Georg Boonen
Independent Researcher
Author Profile
Juergen Drewe
University Clinic, Basel
Author Profile

Abstract

Early treatment of polycythemia vera with ultra-low-dose interferon-α 2a is well tolerated and results in complete hematologic and major molecular remission and a strong reduction of all symptoms, especially pruritus and fatigue.

Peer review status:UNDER REVIEW

24 Jun 2021Submitted to Clinical Case Reports
24 Jun 2021Submission Checks Completed
24 Jun 2021Assigned to Editor
30 Jun 2021Reviewer(s) Assigned
15 Jul 2021Review(s) Completed, Editorial Evaluation Pending
15 Jul 2021Editorial Decision: Revise Minor
06 Aug 20211st Revision Received
09 Aug 2021Assigned to Editor
09 Aug 2021Submission Checks Completed
09 Aug 2021Review(s) Completed, Editorial Evaluation Pending